Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis

S. A. Harrison, S. R. Marri, N. Chalasani, R. Kohli, W. Aronstein, G. A. Thompson, W. Irish, M. V. Miles, S. A. Xanthakos, E. Lawitz, M. Noureddin, T. D. Schiano, M. Siddiqui, A. Sanyal, B. A. Neuschwander-Tetri, P. G. Traber

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background: Non-alcoholic steatohepatitis (NASH) and resultant liver fibrosis is a major health problem without approved pharmacotherapy. Pre-clinical results of GR-MD-02, a galectin-3 inhibitor, suggested potential efficacy in NASH with advanced fibrosis/cirrhosis and prompted initiation of a clinical development programme in NASH with advanced fibrosis. Aim: To evaluate the safety, pharmacokinetics and exploratory pharmacodynamic markers of GR-MD-02 in subjects having NASH with bridging fibrosis. Methods: The GT-020 study was a first-in-human, sequential dose-ranging, placebo controlled, double-blinded study with the primary objective to assess the safety, tolerability and dose limiting toxicity of GR-MD-02, in subjects with biopsy-proven NASH with advanced fibrosis (Brunt stage 3). The secondary objectives were to characterise first-dose and multiple-dose pharmacokinetic profiles and to evaluate changes in potential serum biomarkers and liver stiffness as assessed by FibroScan. Results: GR-MD-02 single and three weekly repeated of 2, 4 and 8 mg/kg revealed no meaningful clinical differences in treatment emergent adverse events, vital signs, electrocardiographic findings or laboratory tests. Pharmokinetic parameters showed a dose-dependent relationship with evidence of drug accumulation following 8 mg/kg (~twofold). Conclusions: GR-MD-02 doses were in the upper range of the targeted therapeutic dose determined from pre-clinical data and were safe and well tolerated with evidence of a pharmacodynamic effect. These results provide support for a Phase 2 development programme in advanced fibrosis due to NASH.

Original languageEnglish (US)
Pages (from-to)1183-1198
Number of pages16
JournalAlimentary Pharmacology and Therapeutics
Volume44
Issue number11-12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Galectin 3
Fatty Liver
Fibrosis
Placebos
Pharmacokinetics
Safety
Vital Signs
Liver Cirrhosis
Clinical Studies
Biomarkers
Biopsy
Drug Therapy
Liver
Health
Therapeutics
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Randomised clinical study : GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. / Harrison, S. A.; Marri, S. R.; Chalasani, N.; Kohli, R.; Aronstein, W.; Thompson, G. A.; Irish, W.; Miles, M. V.; Xanthakos, S. A.; Lawitz, E.; Noureddin, M.; Schiano, T. D.; Siddiqui, M.; Sanyal, A.; Neuschwander-Tetri, B. A.; Traber, P. G.

In: Alimentary Pharmacology and Therapeutics, Vol. 44, No. 11-12, 01.12.2016, p. 1183-1198.

Research output: Contribution to journalArticle

Harrison, SA, Marri, SR, Chalasani, N, Kohli, R, Aronstein, W, Thompson, GA, Irish, W, Miles, MV, Xanthakos, SA, Lawitz, E, Noureddin, M, Schiano, TD, Siddiqui, M, Sanyal, A, Neuschwander-Tetri, BA & Traber, PG 2016, 'Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis', Alimentary Pharmacology and Therapeutics, vol. 44, no. 11-12, pp. 1183-1198. https://doi.org/10.1111/apt.13816
Harrison, S. A. ; Marri, S. R. ; Chalasani, N. ; Kohli, R. ; Aronstein, W. ; Thompson, G. A. ; Irish, W. ; Miles, M. V. ; Xanthakos, S. A. ; Lawitz, E. ; Noureddin, M. ; Schiano, T. D. ; Siddiqui, M. ; Sanyal, A. ; Neuschwander-Tetri, B. A. ; Traber, P. G. / Randomised clinical study : GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. In: Alimentary Pharmacology and Therapeutics. 2016 ; Vol. 44, No. 11-12. pp. 1183-1198.
@article{a39576a5c1924121a6bf156f51f22e4e,
title = "Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis",
abstract = "Background: Non-alcoholic steatohepatitis (NASH) and resultant liver fibrosis is a major health problem without approved pharmacotherapy. Pre-clinical results of GR-MD-02, a galectin-3 inhibitor, suggested potential efficacy in NASH with advanced fibrosis/cirrhosis and prompted initiation of a clinical development programme in NASH with advanced fibrosis. Aim: To evaluate the safety, pharmacokinetics and exploratory pharmacodynamic markers of GR-MD-02 in subjects having NASH with bridging fibrosis. Methods: The GT-020 study was a first-in-human, sequential dose-ranging, placebo controlled, double-blinded study with the primary objective to assess the safety, tolerability and dose limiting toxicity of GR-MD-02, in subjects with biopsy-proven NASH with advanced fibrosis (Brunt stage 3). The secondary objectives were to characterise first-dose and multiple-dose pharmacokinetic profiles and to evaluate changes in potential serum biomarkers and liver stiffness as assessed by FibroScan. Results: GR-MD-02 single and three weekly repeated of 2, 4 and 8 mg/kg revealed no meaningful clinical differences in treatment emergent adverse events, vital signs, electrocardiographic findings or laboratory tests. Pharmokinetic parameters showed a dose-dependent relationship with evidence of drug accumulation following 8 mg/kg (~twofold). Conclusions: GR-MD-02 doses were in the upper range of the targeted therapeutic dose determined from pre-clinical data and were safe and well tolerated with evidence of a pharmacodynamic effect. These results provide support for a Phase 2 development programme in advanced fibrosis due to NASH.",
author = "Harrison, {S. A.} and Marri, {S. R.} and N. Chalasani and R. Kohli and W. Aronstein and Thompson, {G. A.} and W. Irish and Miles, {M. V.} and Xanthakos, {S. A.} and E. Lawitz and M. Noureddin and Schiano, {T. D.} and M. Siddiqui and A. Sanyal and Neuschwander-Tetri, {B. A.} and Traber, {P. G.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1111/apt.13816",
language = "English (US)",
volume = "44",
pages = "1183--1198",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "11-12",

}

TY - JOUR

T1 - Randomised clinical study

T2 - GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis

AU - Harrison, S. A.

AU - Marri, S. R.

AU - Chalasani, N.

AU - Kohli, R.

AU - Aronstein, W.

AU - Thompson, G. A.

AU - Irish, W.

AU - Miles, M. V.

AU - Xanthakos, S. A.

AU - Lawitz, E.

AU - Noureddin, M.

AU - Schiano, T. D.

AU - Siddiqui, M.

AU - Sanyal, A.

AU - Neuschwander-Tetri, B. A.

AU - Traber, P. G.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Non-alcoholic steatohepatitis (NASH) and resultant liver fibrosis is a major health problem without approved pharmacotherapy. Pre-clinical results of GR-MD-02, a galectin-3 inhibitor, suggested potential efficacy in NASH with advanced fibrosis/cirrhosis and prompted initiation of a clinical development programme in NASH with advanced fibrosis. Aim: To evaluate the safety, pharmacokinetics and exploratory pharmacodynamic markers of GR-MD-02 in subjects having NASH with bridging fibrosis. Methods: The GT-020 study was a first-in-human, sequential dose-ranging, placebo controlled, double-blinded study with the primary objective to assess the safety, tolerability and dose limiting toxicity of GR-MD-02, in subjects with biopsy-proven NASH with advanced fibrosis (Brunt stage 3). The secondary objectives were to characterise first-dose and multiple-dose pharmacokinetic profiles and to evaluate changes in potential serum biomarkers and liver stiffness as assessed by FibroScan. Results: GR-MD-02 single and three weekly repeated of 2, 4 and 8 mg/kg revealed no meaningful clinical differences in treatment emergent adverse events, vital signs, electrocardiographic findings or laboratory tests. Pharmokinetic parameters showed a dose-dependent relationship with evidence of drug accumulation following 8 mg/kg (~twofold). Conclusions: GR-MD-02 doses were in the upper range of the targeted therapeutic dose determined from pre-clinical data and were safe and well tolerated with evidence of a pharmacodynamic effect. These results provide support for a Phase 2 development programme in advanced fibrosis due to NASH.

AB - Background: Non-alcoholic steatohepatitis (NASH) and resultant liver fibrosis is a major health problem without approved pharmacotherapy. Pre-clinical results of GR-MD-02, a galectin-3 inhibitor, suggested potential efficacy in NASH with advanced fibrosis/cirrhosis and prompted initiation of a clinical development programme in NASH with advanced fibrosis. Aim: To evaluate the safety, pharmacokinetics and exploratory pharmacodynamic markers of GR-MD-02 in subjects having NASH with bridging fibrosis. Methods: The GT-020 study was a first-in-human, sequential dose-ranging, placebo controlled, double-blinded study with the primary objective to assess the safety, tolerability and dose limiting toxicity of GR-MD-02, in subjects with biopsy-proven NASH with advanced fibrosis (Brunt stage 3). The secondary objectives were to characterise first-dose and multiple-dose pharmacokinetic profiles and to evaluate changes in potential serum biomarkers and liver stiffness as assessed by FibroScan. Results: GR-MD-02 single and three weekly repeated of 2, 4 and 8 mg/kg revealed no meaningful clinical differences in treatment emergent adverse events, vital signs, electrocardiographic findings or laboratory tests. Pharmokinetic parameters showed a dose-dependent relationship with evidence of drug accumulation following 8 mg/kg (~twofold). Conclusions: GR-MD-02 doses were in the upper range of the targeted therapeutic dose determined from pre-clinical data and were safe and well tolerated with evidence of a pharmacodynamic effect. These results provide support for a Phase 2 development programme in advanced fibrosis due to NASH.

UR - http://www.scopus.com/inward/record.url?scp=84995784051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995784051&partnerID=8YFLogxK

U2 - 10.1111/apt.13816

DO - 10.1111/apt.13816

M3 - Article

C2 - 27778367

AN - SCOPUS:84995784051

VL - 44

SP - 1183

EP - 1198

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 11-12

ER -